← Back to Search

Unknown

BMS-986172 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 35 days
Awards & highlights

Study Summary

This study is evaluating whether a drug called BMS-986172 is safe and well tolerated.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 35 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 35 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of AEs leading to discontinuation of study treatment
Incidence of Serious Adverse Events (SAEs)
Incidence of clinically significant changes in ECG parameters: QTcF
+10 more
Secondary outcome measures
Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))
Maximum observed plasma concentration (Cmax)
Plasma concentrations of BMS-986172

Trial Design

4Treatment groups
Experimental Treatment
Group I: Part D: FE/BAExperimental Treatment1 Intervention
FE/BA = Food Effect/Relative Bioavailability
Group II: Part C: JMADExperimental Treatment2 Interventions
JMAD= Japanese Multiple Ascending Dose
Group III: Part B: MADExperimental Treatment2 Interventions
MAD = Multiple Ascending Dose
Group IV: Part A: SADExperimental Treatment2 Interventions
SAD = Single Ascending Dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986172
2021
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,651 Previous Clinical Trials
4,130,531 Total Patients Enrolled
~10 spots leftby Jun 2025